Treat-to-target is a therapeutic concept that considers well defined and specific physiologic targets as aims in controlling the pathophysiology of the disease. It has been widely used in diseases that pathophysiology includes, chronic metabolic and physiological disturbances, namely rheumatic conditions, vascular medicine and diabetes. In diabetes, the availability of "gold-standard" quantitative measures like fasting plasma glucose and glycated hemoglobin make the application of treat-to-target trials especially pertinent. Treatment modalities which have used single therapeutic agents or combinations or in combination with a variety of titration algorithms and implementation protocols have broadened our understanding of diabetes management with specific reference to insulin initiation and maintenance. Treat-to-target trials have been used to investigate a wide variety of questions including efficacy, safety, effect of treatment on comorbidities and patient satisfaction, ideal mechanisms to implement insulin initiation etc. A more generalized acceptance and implementation of treat-to-target trials may finally revolutionize diabetes management by combining aspects of individual care with standard treatment protocols.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3987265 | PMC |
| http://dx.doi.org/10.4103/2230-8210.129106 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Health-care resource use and costs associated with inflammatory bowel disease in northwest London: a retrospective linked database study.
BMC Gastroenterol
December 2024
Department of Inflammatory Bowel Disease, St Mark's National Bowel Hospital, Central Middlesex Hospital, Acton Lane, London, NW10 7NS, UK.
Background: With 20-40% of patients who have inflammatory bowel disease (IBD) not responding to therapy, resource use and costs can be high. We performed a descriptive analysis of health-care data for IBD management in the National Health Service to explore potential areas for improvement.
Methods: In this exploratory study, we analysed real-world data from the Discover dataset for adults with a diagnosis of incident IBD recorded in northwest London, UK, between 31 March, 2016, and 31 March, 2020.
Sustained DMARD-free remission in subgroups of patients with rheumatoid arthritis: an analysis of two prospective cohorts with early arthritis.
Lancet Rheumatol
December 2024
Department of Rheumatology, Erasmus Medical Center, Rotterdam, Netherlands; Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands.
Background: About 20% of patients with rheumatoid arthritis on disease-modifying antirheumatic drugs (DMARDs) can reach sustained DMARD-free remission. Nonetheless, the 2022 EULAR recommendations discourage complete cessation of DMARDs due to flare risk. The evidence behind this recommendation is obtained from trial populations using biological DMARDs, representing only a subgroup of the total population of patients with rheumatoid arthritis.
View Article and Find Full Text PDFThe healthcare system in the United States (US) is complex and often fragmented across national and regional health plans which exhibit substantial variability in benefit design and formulary policies for accessing medications. We propose an access-focused value assessment framework for formulary decision-making for medications to manage immune-mediated inflammatory diseases (IMIDs), where patients are at the center of this framework. Formulary decision-making for IMID medications can be a challenging, even daunting, task with continuously evolving and enhanced treat-to-target goals.
View Article and Find Full Text PDFAdvancements in the management of pediatric inflammatory bowel disease.
Expert Rev Gastroenterol Hepatol
December 2024
SickKids Inflammatory Bowel Disease Centre, Division of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children, Toronto, Canada.
Introduction: The management of pediatric inflammatory bowel disease (PIBD) has drastically changed in the last decade. The limited availability of new biologics or small molecule therapies, and concerns about durability in children has necessitated the development of other advances in management to optimize care.
Areas Covered: This review covers guidance for management targets and advances in optimizing biologic therapies, new medical therapies, adjuvant therapies, precision medicine and mental health concerns in PIBD.
Treat-to-Target Outcomes With Tapinarof Cream 1% in Phase 3 Trials for Plaque Psoriasis.
Cutis
October 2024
Dr. Armstrong is from the Division of Dermatology, University of California Los Angeles. Dr. Bissonnette is from Innovaderm Research Inc, Montreal, Quebec, Canada. Dr. Chovatiya is from Chicago Medical School, Rosalind Franklin University of Medicine and Science, Illinois, and the Center for Medical Dermatology and Immunology Research, Chicago. Dr. Bhutani is from the Department of Dermatology, University of California, San Francisco. Drs. Brown and Tallman are from Dermavant Sciences, Inc, Morrisville, North Carolina. Dr. Papp is from Probity Medical Research Inc and Alliance Clinical Trials, Waterloo, Ontario, Canada, and the University of Toronto, Ontario.
The National Psoriasis Foundation (NPF) treatment targets aim to achieve 1% or lower body surface area (BSA) affected after 3 months of treatment. European psoriasis treatment guidelines aim to achieve similar goals based on improvements in Psoriasis Area and Severity Index (PASI) scores. We performed pooled analyses of the PSOARING phase 3 program, which evaluated treat-to-target outcomes for patients treated with tapinarof cream 1% once daily (QD) for up to 52 weeks.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!